Your fact-checks will appear here
MRNA vaccine against COVID-19 from BioNTech in cooperation with Pfizer
The available analyses collectively identify two core claims: , and . The strongest, repeated evidence for long-term tissue persistence ties to prior infection, while claims that vaccination routinely...
No large-scale studies with more than five years of follow-up on the original Pfizer-BioNTech (Comirnaty/BNT162b2) or Moderna (Spikevax/mRNA-1273) mRNA COVID-19 vaccines are reported in the supplied s...
The evidence across the provided studies indicates , but research shows , and some statistical signals in elderly surveillance warranted further evaluation. The three analyses collectively report that...
Since 2022 there has been of authorized mRNA COVID-19 vaccines, but regulatory updates and market withdrawals of specific products have occurred in some jurisdictions and safety labeling has been revi...
Bivalent COVID-19 boosters combine mRNA or protein from two spike variants—typically the ancestral (Wuhan-like) strain plus an Omicron sublineage—to broaden antibody recognition compared with original...
Only one COVID-19 vaccine manufacturer—Pfizer/BioNTech—has been documented in these sources as having released key subject‑level trial data and broader review documents to regulators and, under court ...
The short answer: yes — in rare instances neurological conditions reported after the Pfizer–BioNTech COVID-19 vaccine have led to lasting deficits, but evidence shows such outcomes are uncommon and th...
Multiple peer‑reviewed and non‑peer sources report vaccine‑derived SARS‑CoV‑2 spike protein can be detected for periods ranging from days to many months after mRNA vaccination, with documented finding...
The publicly available materials in this search set do not list the vaccine ingredients of Comirnaty or explain the function of each excipient; package inserts and product information are mentioned as...
Clinical studies and case series report transient blood-test abnormalities after COVID-19 vaccination, most commonly thrombocytopenia/ITP, transient neutropenia and short-lived changes in coagulation ...
Available studies show myocarditis after mRNA COVID-19 vaccines is rare but concentrated in adolescent and young adult males (excess risk up to ~20 per 100,000 doses in some groups), venous thromboemb...
Available reporting and studies in the provided materials do not support the claim that mRNA COVID-19 vaccines cause a widespread “batch” injury in healthy adult males; surveillance and regulatory sta...
The assembled analyses show a clear consensus: , with common short‑lived reactions and rare serious events such as myocarditis, pericarditis, and anaphylaxis. Postmarketing surveillance and regulatory...
Three manufacturers——have developed and announced variant‑specific COVID‑19 booster formulations in recent seasons, with regulatory actions and company releases spanning 2024–2025 and updates into 202...
The evidence converges that , with highest attributable risks after the second dose in adolescents and young adults. Systematic reviews and large cohort studies put peak estimates roughly between , wh...
The claim "Covid Vaccine deaths/side effects" compresses two different questions: whether COVID-19 vaccines cause increased mortality and how commonly and seriously they produce adverse events. The as...